+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition



Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition



Lancet 387(10033): 2133-2144



Investments in cancer control--prevention, detection, diagnosis, surgery, other treatment, and palliative care--are increasingly needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Cancer (the third volume of nine in Disease Control Priorities, 3rd edition) developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of early breast cancer, cervical cancer, and selected childhood cancers; and widespread availability of palliative care, including opioids. These interventions would cost an additional US$20 billion per year worldwide, constituting 3% of total public spending on health in low-income and middle-income countries. With implementation of an appropriately tailored package, most countries could substantially reduce suffering and premature death from cancer before 2030, with even greater improvements in later decades.

(PDF emailed within 0-6 h: $19.90)

Accession: 057529284

Download citation: RISBibTeXText

PMID: 26578033

DOI: 10.1016/S0140-6736(15)00755-2


Related references

Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet. Diabetes and Endocrinology 6(10): 798-808, 2018

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387(10013): 61-69, 2016

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. Public Health 2(9): E411-E419, 2018

Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet 389(10071): 861-870, 2016

Policy and priorities for national cancer control planning in low- and middle-income countries: Lessons from the Association of Southeast Asian Nations (ASEAN) Costs in Oncology prospective cohort study. European Journal of Cancer 74: 26-37, 2017

Effectiveness of national and subnational infection prevention and control interventions in high-income and upper-middle-income countries: a systematic review. Lancet. Infectious Diseases 18(5): E159-E171, 2017

Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet. Oncology 7(7): 584-595, 2006

Perceptions and impact of plain packaging of tobacco products in low and middle income countries, middle to upper income countries and low-income settings in high-income countries: a systematic review of the literature. Bmj Open 6(3): E010391, 2016

Barriers and facilitators to implementation of essential health benefits package within primary health care settings in low-income and middle-income countries: A systematic review. International Journal of Health Planning and Management 2018, 2018

Targeting the affordability of cigarettes: a new benchmark for taxation policy in low-income and-middle-income countries. Tobacco Control 19(4): 325-330, 2010

Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. Bmj Global Health 2(4): E000453, 2017

Reducing the burden of road traffic injury: translating high-income country interventions to middle-income and low-income countries. Injury Prevention 14(5): 284-289, 2008

The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics 31(11): 1063-1082, 2014

The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization 85(4): 279-288, 2007

The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries. Bulletin of the World Health Organisation 85(4): 279-288, 2007